3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
7
Colorectal Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
COVID-19
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cancer Resectable
1
Neoplasm, Residual
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Klatskin Tumor
1
Hypoxia
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Biliary Tract Neoplasms
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
Hydroxychloroquine
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled